FREMONT, Calif., April 7 /PRNewswire-FirstCall/ -- Curon Medical, Inc. announced that its financial statements for the year ended December 31, 2005, filed with its Annual Report on Form 10-K on March 30, 2006, included an audit report containing a going concern qualification. Its announcement is made in compliance with Nasdaq’s Marketplace Rule requiring that Nasdaq-listed companies make a separate announcement by press release when they receive an audit opinion containing a going concern qualification.
(Logo: http://www.newscom.com/cgi-bin/prnh/20050318/CURONLOGO )
About Curon Medical, Inc.
Curon Medical develops, manufactures and markets innovative proprietary products for the treatment of gastrointestinal disorders. The company’s products and products under development consist of radiofrequency generators and single use disposable devices. Its first product, the Stretta System, received U.S. Food and Drug Administration clearance in April 2000 for the treatment of gastroesophageal reflux disease, commonly referred to as GERD. The company’s Secca System for the treatment of bowel incontinence received clearance from the FDA in March 2002. For more information on the company or its products, please visit the company’s website at http://www.curonmedical.com.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20050318/CURONLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comCuron Medical, Inc.
CONTACT: Larry C. Heaton II, President and Chief Executive Officer,+1-510-661-1801, lheaton@curonmedical.com, or Alistair F. McLaren, VicePresident, Chief Financial Officer, +1-510-661-1803,amclaren@curonmedical.com, both of Curon Medical, Inc.; or InvestorRelations: Melody A. Carey of Rx Communications Group, LLC,+1-917-322-2571, mcarey@rxir.com, for Curon Medical, Inc.
Web site: http://www.curonmedical.com/
